

**STATEMENT BY THE DELEGATION OF THE REPUBLIC OF INDONESIA
ON AGENDA 14, 21.2
THE 150TH SESSION OF THE WHO EXECUTIVE BOARD**

Thank you chair.

This statement is for both item 14 and item 21.1 on the agenda.

On item 14, Indonesia takes note of the Secretariat's report.

We support the need to map existing nomenclature systems as a critical steps to establishing an effective strategy to medical device nomenclature standardization.

On item 21.1, Indonesia supports and co-sponsors the decision to extend the mandate of the Global strategy and plan of action on public health, innovation and intellectual property.

The comprehensive implementation of the GSPOA-PHI and the principle enshrines in it, will make a substantial contribution in promoting equity in global health.

We continue to support the GSPOA-PHI implementation through among others, promoting the enhancement of local and regional pharmaceutical and medical device production, as well as supporting the discussion on the TRIPS waiver proposal for COVID-19.

Nevertheless, in the implementation of the GSPOA-PHI, consideration should also be taken on the results of any scientific processes aimed at elevating the scientific value of a locally produced, natural-based herbal medicine compound and products.

There is also a need to take into account the unique focus and strategy of each country in implementing the GSPOA-PHI, particularly in light of the current pandemic.

To critically assess the strategy, we welcome the 2nd survey by the secretariat to collect data on the implementation and evaluation of GSPOA-PHI.

We hope this provides a better clarity to determining the next steps, including if any adjustment is needed.

.

I thank you.